MNKD - MANNKIND CORP
IEX Last Trade
6.81
0.150 2.203%
Share volume: 30,150
Last Updated: Thu 26 Dec 2024 08:30:06 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$6.66
0.15
2.25%
Fundamental analysis
27%
Profitability
19%
Dept financing
25%
Liquidity
51%
Performance
30%
Performance
5 Days
-3.99%
1 Month
2.43%
3 Months
7.50%
6 Months
29.87%
1 Year
85.67%
2 Year
32.42%
Key data
Stock price
$6.81
DAY RANGE
$6.60 - $6.73
52 WEEK RANGE
$3.28 - $7.63
52 WEEK CHANGE
$82.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Michael E. Castagna
Region: US
Website: mannkindcorp.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: mannkindcorp.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
MannKind focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism.
Recent news